Blinatumomab: a historical perspective.

Abstract

For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal antibodies, irradiation and/or hematopoietic stem cell transplantation are added. However, the current standard of care--particularly for patients with relapsed disease--is often not sufficient to achieve durable remissions. A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT103 or AMG 103). This bispecific antibody construct has dual specificity for CD19 and CD3 and belongs to the class of bispecific T cell engager (BiTE®) antibodies, which can potentially engage all cytotoxic T cells of a patient for redirected lysis of tumor cells. Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia.

• Authors: Dirk Nagorsen, Peter Kufer, Patrick A Baeuerle, Ralf Bargou
• Journal: Pharmacology & therapeutics (Pharmacol Ther) Vol. 136 Issue 3 Pg. 334-42 (Dec 2012) ISSN: 1879-016X [Electronic] England
• PMID: 22940266 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Bispecific
• blinatumomab

Topics

• Animals
• Antibodies, Bispecific (administration & dosage, chemistry, therapeutic use)
• Clinical Trials as Topic
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Lymphoma, Mantle-Cell (drug therapy)
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)